Platelet response type self-gelation hemostatic material as well as preparation method and application thereof
By combining oxidized alginate grafted with borate ester bonds and hydroxylated small intestinal submucosa, a self-gelling hemostatic material was designed, which solved the problem that existing hemostatic powders could not form a stable barrier, and achieved high adhesion strength and rapid hemostasis, making it suitable for severely bleeding wounds.
Patent Information
- Application Number
- CN202411146242.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-20
AI Technical Summary
Existing hemostatic powders cannot form a stable physical barrier on the wound surface, resulting in insufficient hemostasis in severely bleeding wounds, poor adhesion strength, and failure to effectively utilize the hemostatic effect of platelets.
Using boronic acid ester graft-modified oxidized alginate and hydroxylated submucosa of the small intestine as raw materials, a self-gelling hemostatic material is formed through dynamic covalent and non-covalent interactions, realizing the powder-gel transformation and promoting platelet adhesion and activation.
It improves the adhesion strength and puncture pressure of hemostatic materials, enabling them to form a stable physical barrier in a short time, promote the coagulation process, accelerate hemostasis, and meet the hemostasis needs under the condition of first-degree hypertension.
Smart Images

Figure CN119015481A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and in particular relates to a platelet-responsive self-gelling hemostatic material and a preparation method and application thereof. Background Art
[0002] Acute trauma often occurs in military training and daily life. Uncontrollable bleeding and wound infection after tissue damage are the main causes of casualties. Therefore, efficient hemostasis is crucial to improving patient survival rates in first aid. Powder materials have a large specific surface area and excellent liquid absorption capacity, which can concentrate coagulation-related substances in the blood and promote the formation of blood clots, making them an ideal choice for hemostatic materials. However, traditional hemostatic powders are easily washed away by blood flow and cannot form a stable physical barrier on the wound surface, which affects their ability to stop bleeding in severe bleeding wounds.
[0003] In physiological hemostasis, platelets play an extremely important role. They quickly "recognize" the site of injury and adhere to the exposed subendothelial collagen, activating the rapid formation of platelet hemostatic plugs. Platelet activation is a necessary condition for the activation of coagulation factors. The development of hemostatic powder with platelet responsiveness is expected to accelerate the hemostatic process and achieve good hemostatic effects.
[0004] The patent (CN115814148B) reported a hemostatic material (AM7-CS3) prepared from sodium alginate and carboxymethyl chitosan, which has two application forms: hydrogel and powder. However, the material has poor adhesion strength, and the enhancement effect of blood on its gelation process and other properties is not reported. Summary of the invention
[0005] In order to solve the problems existing in the prior art, the object of the present invention is to provide a platelet-responsive self-gelling hemostatic material and a preparation method and use thereof.
[0006] The invention provides a self-gelling hemostatic material, which is prepared from the following raw materials in parts by weight: 1-5 parts of oxidized alginate modified by borate bond grafting and 0.01-1 parts of hydroxylated small intestinal submucosal layer.
[0007] Furthermore, it is prepared from the following raw materials in parts by weight: 1 part of oxidized alginate modified by borate bond grafting, and 0.3 part of hydroxylated small intestinal submucosal layer.
[0008] Furthermore, the self-gelling hemostatic material is a self-gelling hemostatic hydrogel material or a self-gelling hemostatic powder material.
[0009] Furthermore, the borate bond grafted modified oxidized alginate is 3-aminophenylboronic acid grafted modified oxidized alginate, and the oxidized alginate is preferably sodium oxidized alginate; the hydroxylated small intestinal submucosa is small intestinal submucosa modified by 3-amino-1,2-propanediol, and the small intestinal submucosa is preferably porcine small intestinal submucosa.
[0010] Furthermore, the synthesis method of the borate bond grafted modified oxidized alginate comprises the following steps:
[0011] (1) dissolving alginate and an oxidant in a solvent, and obtaining oxidized alginate after reaction;
[0012] (2) dissolving oxidized alginate and an activator in a solvent, adding 3-aminophenylboric acid solution, and obtaining oxidized alginate grafted with borate bonds after reaction.
[0013] Furthermore, in step (1), the oxidant is sodium periodate; the mass ratio of the alginate to the oxidant is 1:0.1-0.5; the solvent of the reaction is an organic solvent; the reaction temperature is 10-40°C and the reaction time is 4-8 hours;
[0014] Preferably, the mass ratio of the alginate to the oxidant is 1:0.25; the solvent of the reaction is anhydrous ethanol; the temperature of the reaction is 20-30°C, and the reaction time is 6 hours;
[0015] Furthermore, after the reaction in step (1) is completed, dialysis treatment is required, and the molecular weight cutoff of the dialysis bag is 2 to 5 KDa; the dialysis is performed in deionized water for 2 to 4 days, and the water is changed 2 to 4 times a day;
[0016] Preferably, the molecular weight cut-off of the dialysis bag is 3.5 KDa; the dialysis is performed in deionized water for 3 days, with the water being changed 3 times a day;
[0017] In step (2), the activator is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; the solvent of the reaction is an inorganic solvent; the molar ratio of the oxidized alginate, the activator and the 3-aminophenylboronic acid is 1:1-5:1-3; the solvent in the 3-aminophenylboronic acid solution is an organic solvent; the reaction temperature is 10-40°C and the reaction time is 20-30 hours.
[0018] Preferably, in step (2), the solvent of the reaction is water; the molar ratio of the oxidized alginate, the activator and the 3-aminophenylboronic acid is 1:3:2; the solvent in the 3-aminophenylboronic acid solution is anhydrous ethanol; the temperature of the reaction is 20-30°C and the reaction time is 24 hours.
[0019] Furthermore, the method for synthesizing the hydroxylated small intestinal submucosa comprises the following steps:
[0020] (i) reacting the small intestinal submucosa, acid and enzyme to obtain a small intestinal submucosa digestive fluid;
[0021] (ii) The small intestinal submucosa digestive juice, 3-amino-1,2-propanediol and an activator are dissolved in a solvent and reacted to obtain a hydroxylated small intestinal submucosa.
[0022] Furthermore, in step (i), the acid is hydrochloric acid; the enzyme is pepsin; the mass ratio of the small intestinal submucosal layer to the enzyme is 1:0.05-0.3; the reaction temperature is 20-30°C and the reaction time is 20-100 hours;
[0023] Preferably, in step (i), the mass ratio of the small intestinal submucosal layer to the enzyme is 1:0.01-0.25, preferably 1:0.2; the reaction temperature is 25°C, and the reaction time is 24 to 96 hours, preferably 72 hours;
[0024] Furthermore, before the reaction in step (i) begins, the small intestinal submucosal layer needs to be powdered and sieved, and the mesh size is 100 to 300 meshes; in step (i), the pH needs to be adjusted, and the pH range is 1 to 3;
[0025] Preferably, in step (i), the mesh size is 200 mesh; the pH range is 2;
[0026] In step (ii), the activator is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; the mass ratio of the small intestinal submucosal layer to 3-amino-1,2-propanediol is 1:0.5-6; the amount of 3-amino-1,2-propanediol to the activator is 1:0.5-5; the solvent is an inorganic solvent; the reaction temperature is 10-40°C and the reaction time is 20-30 hours.
[0027] Furthermore, in step (ii), the mass ratio of the small intestinal submucosal layer and 3-amino-1,2-propanediol is 1:1-5, preferably 1:3; the amount of 3-amino-1,2-propanediol and the activator is 1:1-3, preferably 1:1.5; the solvent is water; the pH is adjusted to 5-6 using an inorganic sodium salt solution or an inorganic acid solution; the reaction temperature is 20-30°C and the reaction time is 24 hours.
[0028] Furthermore, in step (ii), it is also necessary to adjust the pH, and the pH is adjusted to 4-7 using an alkaline solution or an acid solution.
[0029] The present invention also provides a method for preparing the above-mentioned self-gelling hemostatic material, which comprises the following steps: dissolving the oxidized alginate modified by grafting of borate bonds and the hydroxylated small intestinal submucosa in solvents respectively, then mixing the oxidized alginate solution modified by grafting of borate bonds and the hydroxylated small intestinal submucosa solution, adjusting the pH, and forming a self-gelling hemostatic hydrogel material; or, the method further comprises the following steps: freeze-drying and grinding the hydrogel to obtain a self-gelling hemostatic powder material.
[0030] Furthermore, the solvent is an inorganic solvent or an organic solvent; the volume ratio of the boronate bond grafted modified oxidized alginate solution to the hydroxylated small intestinal submucosal solution is 1:0.05-2.5; and the pH adjustment range is 6-10.
[0031] Furthermore, the solvent is a phosphate buffered saline solution, water or physiological saline, preferably, the solvent is a phosphate buffered saline solution; the volume ratio of the boronate bond grafted modified oxidized alginate solution and the hydroxylated small intestinal submucosal solution is 1:0.1-2, preferably 1:1; the pH adjustment range is 7-9, preferably 8.
[0032] The present invention also provides use of the self-gelling hemostatic material in preparing a hemostatic material.
[0033] Compared with the patent (CN115814148B), the present invention has achieved the following beneficial effects:
[0034] (1) The adhesion strength of the AP / SIS-OH hydrogel of the present invention is 80.07 KPa, while the adhesion strength of the AM7-CS3 hydrogel is about 9.50 KPa, so the AP / SIS-OH hydrogel of the present invention has better adhesion strength;
[0035] (2) When blood is used as the medium to trigger gelation, the adhesion strength of the AP / SIS-OH of the present invention is increased to 109.7 KPa, while there is no relevant report on AM7-CS3 hemostatic powder. Therefore, the AP / SIS-OH of the present invention has platelet activation-mediated adhesion enhancement performance;
[0036] (3) The bursting pressure of the AP / SIS-OH hemostatic powder of the present invention is 154.90 mmHg, while the bursting pressure of the AM7-CS3 hemostatic powder is 129.00 mmHg, which can basically meet the application in the case of primary hypertension (systolic pressure 140-159 mmHg, diastolic pressure 90-99 mmHg). Therefore, the AP / SIS-OH hemostatic powder of the present invention has a better bursting pressure.
[0037] In summary, the present invention provides a platelet-responsive self-gelling hemostatic material and its preparation method and use. Based on multiple cross-linking strategies such as dynamic covalent bonds and non-covalent interactions, the present invention uses sodium alginate modified by phenylboronic acid grafting and hydroxylated porcine small intestinal submucosal layer as raw materials to design a hemostatic material that can quickly achieve self-gelling. The hemostatic material has good hydrophilicity and liquid absorption capacity, can achieve powder-gel transformation in a short time, form a stable physical barrier, has platelet response characteristics, can promote platelet adhesion and activation, accelerate the body's coagulation process, and improve the mechanical properties and tissue adhesion of the material, and has good application prospects.
[0038] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0039] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 (a) Synthesis schematic diagram and (bc) H NMR spectra of ADA-PBA and SIS-OH.
[0041] Figure 2 IR spectra of AP, AP / SIS and AP / SIS-OH.
[0042] Figure 3 This is the microscopic surface morphology of AP / SIS-OH powder.
[0043] Figure 4 AP / SIS-OH Hemostatic Powder and Celox TM Absorption of (a) PBS and (b) anticoagulated whole blood by hemostatic powder; (c) liquid absorption rate of PBS and blood by different hemostatic powders; (d) Photo of the rapid powder-gel transformation of AP / SIS-OH powder (****p<0.0001).
[0044] Figure 5 (a) Stress-strain curves and (b) compressive strengths of AP, AP / SIS and AP / SIS-OH hemostatic powders after gelation transformation; (c) rheological evaluation and (d) photos of self-healing properties of AP / SIS-OH (**p<0.01, ns: no significant difference).
[0045] Figure 6(a) CCK-8 and (b) live / dead staining results of BRL cells on days 1, 3, and 5 after treatment with AP, AP / SIS, and AP / SIS-OH (scale bar = 200 μm) (ns: no significant difference).
[0046] Figure 7 The SSC-A and CD62p of platelets after different treatments + (a) Flow cytometry results and (b, c) corresponding statistical results; ELISA results of (d) P-selectin and (e) GP IIb / IIIa expression on the cell membrane of platelets after treatment with different materials for 1 and 5 min (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: no significant difference).
[0047] Figure 8 (a) The sealing experiment of AP / SIS-OH on damaged pig lung and stomach; (b) The bursting strength of different groups of hemostatic powders; (c) The rheological properties of materials after PRP triggered gelation of different hemostatic powders and (d) SEM images of the AP / SIS-OH group (low-magnification image: scale bar = 30 μm; high-magnification image: scale bar = 10 μm); (e) The tissue adhesion strength of AP / SIS-OH after contact with PBS, PPP, PRP and anticoagulated whole blood (*p<0.05, **p<0.01, ***p<0.001, ns: no significant difference).
[0048] Fig. 9 (a) Pictures of the hemostasis process of different materials applied to the rabbit liver bleeding model and (b) pictures of the filter paper after hemostasis; (c, d) the amount of bleeding and hemostasis time after hemostasis with different materials (*p<0.05, **p<0.01, ***p<0.001).
[0049] Fig.10 (a) Picture of the hemostatic process of AP / SIS-OH hemostatic powder applied to the rabbit heart perforation bleeding model and (b) HE staining results of its adhesion on the heart surface; (c) The sealing and hemostatic effect of AP / SIS-OH hemostatic powder on rabbit femoral artery perforation bleeding, (d) bleeding situation and (e) bleeding amount (**p<0.01). DETAILED DESCRIPTION
[0050] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0051] The "room temperature" referred to in the present invention is 25±5°C.
[0052] Example 1: Preparation of platelet-responsive self-gelling hemostatic material
[0053] 1. Synthesis of modified sodium alginate
[0054] (1) Disperse sodium alginate in anhydrous ethanol at a ratio of 2% (unit: g / mL) and stir continuously to obtain a sodium alginate / anhydrous ethanol dispersion system. Dissolve NaIO4 in water of the same volume as the anhydrous ethanol to obtain a NaIO4 solution. The mass of NaIO4 is 0.25 times that of sodium alginate.
[0055] (2) Under light-proof conditions, the NaIO4 solution was added dropwise to the sodium alginate / anhydrous ethanol dispersion system and reacted at room temperature for 6 h. After the reaction was completed, 15 mL of ethylene glycol was added and stirred for 30 min to terminate the reaction.
[0056] (3) The reaction product was placed in a dialysis bag (molecular weight cut-off: 3.5 KDa), and dialyzed in deionized water for 3 days, with the water changed 3 times a day. After dialysis, the sample was freeze-dried to obtain a sample (abbreviated as ADA sample).
[0057] (4) The ADA sample was completely dissolved in water at a concentration of 0.5% (unit: g / mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) was added and stirred until it was completely dissolved. The molar ratio of ADA to EDC was 1:3.
[0058] (5) Dissolve 3-aminophenylboronic acid (PBA) in anhydrous ethanol and add the ADA solution dropwise. Adjust the pH to 7 and react at room temperature for 24 hours. The molar ratio of ADA to PBA is 1:2.
[0059] (6) After the reaction is completed, the dialysis and freeze-drying steps are the same as step (3) to obtain a modified sodium alginate sample (abbreviated as ADA-PBA sample).
[0060] 2. Synthesis of Hydroxylated Porcine Intestinal Submucosa
[0061] (1) Preparation of porcine small intestinal submucosal (SIS) digestive fluid: The decellularized SIS was ground into powder using a ball mill and passed through a 200-mesh sieve to prepare SIS powder. 0.3 g of SIS powder was added to 30 mL of hydrochloric acid solution (pH = 2), and then 50 mg of pepsin was added. The mixture was stirred at 25°C for 72 h to prepare SIS digestive fluid.
[0062] (2) 3-Amino-1,2-propanediol (APD, 0.9 g) was dissolved in 10 mL of water to prepare an APD solution.
[0063] (3) Add 30 mL of SIS digestion solution (containing 0.3 g of SIS) to 150 mL of water. After sufficient dissolution and dilution, add APD solution dropwise. Then add EDC to the reaction system, the amount of which is 1.5 times that of APD. Adjust the pH of the system to 5-6 with NaOH solution or HCl solution and react at room temperature for 24 hours.
[0064] (4) After the reaction is completed, the reaction product is placed in a dialysis bag (molecular weight cutoff is 3.5 KDa) and dialyzed in deionized water for 3 days, with the water changed 3 times a day. After dialysis, the product is freeze-dried to obtain a hydroxylated porcine small intestinal submucosal sample (abbreviated as SIS-OH sample).
[0065] 3. Preparation of Platelet-responsive Self-gelling Hemostatic Powder
[0066] (1) The freeze-dried ADA-PBA was dissolved in phosphate buffered saline (PBS) at a mass volume ratio of 10% (g / mL) for later use.
[0067] (2) The freeze-dried SIS-OH was dissolved in phosphate buffered saline (PBS) at a mass volume ratio of 3% (g / mL) for later use.
[0068] (3) The solutions in step (1) and step (2) were mixed at a volume ratio of 1:1, and the pH value was adjusted to 8 to form the final hydrogel (abbreviated as AP / SIS-OH hydrogel).
[0069] (5) After the AP / SIS-OH hydrogel was freeze-dried, hemostatic powder (abbreviated as AP / SIS-OH hemostatic powder) was prepared by physical grinding method.
[0070] The following comparative samples are prepared by comparative examples.
[0071] Comparative Example 1, Preparation of Hemostatic Powder
[0072] The freeze-dried ADA-PBA of Example 1 was dissolved in a phosphate buffered saline solution (PBS) at a mass volume ratio of 10% (g / mL), and the pH value thereof was adjusted to 8 to obtain a hydrogel. After freeze-drying, the hemostatic powder was obtained by a physical grinding method.
[0073] This hemostatic powder is referred to as AP hemostatic powder.
[0074] Comparative Example 2: Preparation of hemostatic powder
[0075] Referring to the method of Example 1, the only difference is that SIS-OH is replaced by untreated porcine small intestinal submucosal (SIS) digestive fluid, the amount of SIS used is the same as SIS-OH in Example 1, and the other conditions are also the same to prepare hemostatic powder. The hemostatic powder is referred to as AP / SIS hemostatic powder.
[0076] The beneficial effects of the present invention are demonstrated by experimental examples below.
[0077] Experimental Example 1: Structural Characterization of Hemostatic Powder
[0078] 1. Experimental methods
[0079] The successful synthesis of ADA-PBA and SIS-OH was verified by NMR spectroscopy.
[0080] The chemical structures of AP, AP / SIS and AP / SIS-OH were characterized by Fourier transform infrared absorption spectroscopy. 2. Experimental results
[0081] result( Figure 1 ) shows that there is a proton peak at δ = 7-8 ppm belonging to the hydrogen atoms of the benzene ring, proving the successful grafting of PBA ( Figure 1 b); A strong proton peak was formed at δ = 2.81 ppm, which was attributed to the methylene contained in the APD, proving that SIS was successfully hydroxylated ( Figure 1 c).
[0082] from Figure 2 It can be seen that compared with the infrared spectrum of AP, AP / SIS is at 3372cm -1 A new absorption peak appeared at the position of 1376cm. This absorption peak is a characteristic absorption peak of hydroxyl. This is because SIS contains substances with hydroxyl groups. After the reaction of AP and SIS-OH, a new absorption peak appeared at 1376cm -1 The absorption peak of BO bond is obvious, which is because after SIS is modified with dihydroxyl group, it can form more borate ester bonds with ADA-PBA. -1 ) than the hydrogen bond absorption peak (3281cm -1 ), indicating that the hydroxyl groups reacted more with the dihydroxyphenylboryl groups, reducing the hydrogen bonds formed between the free hydroxyl groups. The experimental results showed that ADA-PBA and SIS-OH had been successfully synthesized, and the hydroxyl groups in AP / SIS-OH formed borate ester bonds with the dihydroxyphenylboryl groups.
[0083] Experimental Example 2: Performance Test of Hemostatic Powder
[0084] 1. Experimental methods
[0085] (1) The microscopic surface morphology of AP / SIS-OH powder was observed by atomic force microscopy. The test method was as follows: AP / SIS-OH powder was evenly spread on a glass substrate, gelled with PBS and PRP, respectively, and stabilized at 37°C for 5 min.
[0086] (2) Liquid absorption capacity test: One of the outstanding advantages of powdered hemostatic materials is that they have a large specific surface area and can quickly absorb liquid. Therefore, the liquid absorption capacity of AP / SIS-OH was evaluated by a static water contact angle meter, and the commercial hemostatic powder Celox TM , zeolite hemostatic powder (Zeolite) and Yunnan Baiyao hemostatic powder (YB) were used as control substances.
[0087] (3) Mechanical properties test: The mechanical properties of AP / SIS-OH were determined by uniaxial compression test.
[0088] (4) Self-healing performance test: The self-healing properties of AP / SIS-OH were evaluated using the step strain scanning mode of the rheometer.
[0089] (5) Procoagulant activity test: Platelet P-selectin (i.e., CD62p) and glycoprotein GP IIb / IIIa are considered markers of platelet activation. When platelets are activated, the expression site of P-selectin rapidly changes from the surface of the platelet α granule membrane to the cell membrane surface, and subsequently mediates the adhesion of granulocytes and monocytes to platelets; similarly, in the resting state, platelet GP IIb and GP IIIa are independent glycoproteins. After activation, GP IIb and GPIIIa form heterodimers, namely GP IIb / IIIa. It is a receptor for fibrinogen and von Willebrand factor (vWF), mediating aggregation between platelets. Therefore, the procoagulant activity is evaluated by platelet activation experiments. First, AP, AP / SIS, and AP / SIS-OH are incubated with platelets, and the platelet granule size and CD62p are measured by flow cytometry. + The expression of the gene was analyzed, and then the fluorescence signal intensity of SSC-A was statistically analyzed.
[0090] (6) Animal hemostatic effect test: A rabbit liver defect bleeding model was used to evaluate the hemostatic effect of the adhesive hydrogel. A 10 mm diameter and 5 mm deep incision was made on the rabbit liver using a skin biopsy instrument, and the material was immediately covered on the incision. The bleeding process was recorded until complete hemostasis. In addition to the AP, AP / SIS, and AP / SIS-OH groups, clinical fibrin glue (FB) and Celox TM The hemostatic powder was the positive control group, and the blank control group was the control group without hemostatic treatment. The hemostatic effectiveness of the material on massive bleeding was evaluated by rabbit heart perforation bleeding model and rabbit femoral artery perforation bleeding model.
[0091] 2. Experimental results
[0092] from Figure 3It can be seen that in the PBS group, the gel showed a flat and uniform morphology; while in the PRP group, a fiber network structure was observed on the gel surface, proving that AP / SIS-OH powder activated platelets and cooperated with fibrinogen to form a fibrin network.
[0093] result( Figure 4 a, 4b) show that within 1s of contact with AP / SIS-OH, the droplets of PBS / anticoagulated whole blood were rapidly absorbed. However, within the same time, Celox TM There was no obvious liquid absorption phenomenon. Then, the liquid absorption rate of different materials was further measured. The results are as follows Figure 4 As shown in c, Celox TM The PBS absorption rates of AP, AP / SIS and AP / SIS-OH were 321.2%, 287.9% and 272.8% respectively, while the PBS absorption rates of AP, AP / SIS and AP / SIS-OH were 894.1%, 889.7% and 828.5% respectively, which were significantly better than the commercial hemostatic powders compared. Similarly, when anticoagulated whole blood was used as the absorption liquid, the liquid absorption rates of AP, AP / SIS and AP / SIS-OH were still significantly higher than those of the other three groups. The above results demonstrate the excellent hydrophilicity and liquid absorption capacity of AP, AP / SIS and AP / SIS-OH materials. Figure 4 d shows the powder-gel transformation process of AP / SIS-OH. After absorbing the liquid, the powder quickly transforms into a gel-like substance within 3 s based on multiple covalent / non-covalent cross-linking methods.
[0094] Figure 5 The results showed that AP, AP / SIS and AP / SIS-OH hydrogels all exhibited similar properties, and no obvious stress mutation point appeared during the compression process, proving that the materials were not damaged. The compressive strengths of AP, AP / SIS and AP / SIS-OH hydrogels were 50.5KPa, 59.8KPa and 92.5KPa, respectively. Figure 5 b), the mechanical properties of AP / SIS-OH hydrogel are the best. Figure 5 The results in Figure c show that when 300% strain is applied to the AP / SIS-OH hydrogel, the loss modulus (G”) is greater than the storage modulus (G'), indicating that the hydrogel is destroyed. However, when a small strain (1%) is applied, the storage modulus (G') of the hydrogel is greater than the loss modulus (G”), restoring the viscoelastic properties, proving that the AP / SIS-OH hydrogel has good self-healing properties. Figure 5 d shows that two pieces of AP / SIS-OH hydrogels did not break even when subjected to tension after contact, intuitively demonstrating their self-healing properties.
[0095] Figure 6The results of a showed that the extracts of AP, AP / SIS and AP / SIS-OH did not show cytotoxicity compared with the control group after co-culture with rat liver cell line (BRL cells) for 1, 3 and 5 days, indicating that the materials did not affect cell proliferation. The live / dead staining results ( Figure 6 b) It can be seen that the field of view is basically full of living cells with green fluorescence, and dead cells with red fluorescence are rare. In addition, after co-culture with the hydrogel extract, the cells maintained their long spindle shape and were in good condition. In short, AP, AP / SIS and AP / SIS-OH hydrogels did not affect the proliferation and activity of cells, indicating that they have good cell compatibility.
[0096] Figure 7 In the results of ad, the two parameters of forward scatter (FSC) and side scatter (SSC) can reflect the size and complexity of cells, as well as the aggregation of platelets. By statistically analyzing the fluorescence signal intensity of SSC-A, it was shown that AP / SIS and AP / SIS-OH can significantly promote platelet aggregation. In the control group, the intensity of platelet SSC-A in the resting state was 1.33×103, while the AP, AP / SIS and AP / SIS-OH groups were 1.69, 3.47 and 3.43 times of its intensity. In addition, the introduction of SIS and hydroxylated SIS components greatly promoted platelet aggregation. By measuring the platelet activation indicator CD62p + Statistics showed that SIS has procoagulant activity that promotes platelet activation. Furthermore, P-selectin and glycoprotein GP IIb / IIIa on the platelet cell membrane surface were extracted and quantitatively analyzed by ELISA. The results are as follows: Figure 7 e and 7f. After the platelets were in contact with the material for 1 minute, there were significant differences in P-selectin and GP IIb / IIIa between the different groups, which was similar to the incubation for 5 minutes, indicating that the reaction between AP, AP / SIS and AP / SIS-OH and platelets can occur in a very short time. At 1 minute of incubation, the content of P-selectin in the control group was 9.5pg / mL, while the content in the AP, AP / SIS and AP / SIS-OH groups was 1.01, 1.50 and 1.63 times that; similarly, the content of GP IIb / IIIa in the control group was 458.3U / mL, while the content in the AP, AP / SIS and AP / SIS-OH groups was 1.75, 2.52 and 3.10 times that. This shows that AP has a relatively weak ability to activate platelets, while the addition of SIS components significantly promotes the platelet activation process, reflecting its procoagulant activity.
[0097] Effective wound closure is very important in the application of hemostatic materials. The hemostatic powder prepared in this study exhibits rapid powder-gel transformation characteristics and quickly forms a gel barrier with good mechanical properties in a very short time. Figure 8 As shown in a, its wound sealing ability was first verified by sealing the damaged lung and stomach, and air and water were injected into them to check the airtightness. After the damaged organ was sealed with AP / SIS-OH hemostatic powder, no rupture occurred during the subsequent injection of air and water, which can meet the normal filling and expansion of the organ. TM The bursting pressures of AP, AP / SIS and AP / SIS-OH groups were 47.06 mmHg, 88.69 mmHg, 95.81 mmHg, 154.9 mmHg ( Figure 8 b). In general, the normal systolic blood pressure of an adult should be less than 120 mmHg. Therefore, AP / SIS-OH can meet the ability to resist normal blood pressure and has application value in cardiac and arterial hemostasis and closure.
[0098] As mentioned above, the addition of SIS components makes the material have good procoagulant activity. This means that the material has the ability to quickly activate the coagulation system and induce rapid clot formation. Therefore, the rheological properties of AP, AP / SIS and AP / SIS-OH groups were evaluated when platelet-rich plasma (PRP) was used as the medium to trigger gelation. The results are shown in Figure 2. Figure 8 As shown in Figure c, the AP, AP / SIS, and AP / SIS-OH groups all showed an increase in storage modulus over time. However, the modulus increase rate of AP / SIS and AP / SIS-OH was significantly better than that of AP, indicating that blood quickly formed blood clots in them, reflecting the procoagulant activity of the material. The microstructure of AP / SIS-OH after PRP was triggered was evaluated by scanning electron microscopy. Figure 8 d It can be seen that on the basis of the typical hydrogel porous structure, more fibrous structures appear, which is the fibrin network formed by PRP. In order to further explore the effect of different gelation conditions on the tissue adhesion properties of the material, PBS, platelet-poor plasma (PPP), PRP and whole blood were selected as the medium to trigger the gelation of AP / SIS-OH, and the tissue adhesion strength was evaluated by lap shear test, which were 80.07KPa, 75.80KPa, 125.4KPa, 109.7KPa ( Figure 8e). When PRP was used as the medium to trigger gelation, the material showed the best tissue adhesion strength, while the results of the PPP group and the PBS group were similar. The difference between PRP and PPP is mainly reflected in the number of platelets, which shows that platelets have a significant effect on the adhesion properties of the material. The SIS component can promote the activation of platelets, which induces the formation of a fibrin network on the basis of the gel network of the material itself, thereby enhancing the cohesion of the gel system. Moreover, such a material and the fibrin network do not exist separately. They use the collagen topological structure and platelet adhesion sites in SIS as connection points to form an in situ enhanced double network structure, reflecting the adhesion enhancement performance mediated by platelet activation.
[0099] From the experimental results ( Fig. 9 From ab), it can be seen that the area occupied by blood on the filter paper in the blank control group is the largest, while the other groups show obvious hemostatic effects, among which the area in the AP / SIS-OH group is the smallest. Fig. 9 The quantitative statistical results of the bleeding volume and hemostasis time of cd also show that the average bleeding volume of the blank control group was 3.19g, while that of FB and Celox TM The bleeding volume of AP / SIS-OH group was the least (0.72 g), the bleeding time was the shortest (138.5 s), and the hemostatic effect was the best, which was better than the commercial fibrin glue and Celox. TM Hemostatic powder.
[0100] result( Fig.10 a) shows that under extremely high blood pressure, blood splashes out from the perforation, and AP / SIS-OH can successfully seal the hole. Fig.10 b HE staining also shows that the powder can quickly form a gel barrier after application and firmly adhere to the heart surface. Similarly, AP / SIS-OH also showed excellent hemostatic effect in the rabbit femoral artery perforation bleeding model ( Fig.10 ce). Compared with the gauze compression hemostasis method in the control group, the amount of bleeding was significantly reduced, only 0.26g.
[0101] It can be seen from the above experimental results that the AP / SIS-OH material of the present invention exhibits excellent hydrophilicity and liquid absorption capacity, excellent mechanical properties and good self-healing properties, good cell compatibility, can significantly promote platelet aggregation, has good bursting pressure, meets the ability to resist normal blood pressure, and has excellent hemostatic effect.
[0102] In summary, the present invention provides a platelet-responsive self-gelling hemostatic material and its preparation method and use. Based on multiple cross-linking strategies such as dynamic covalent bonds and non-covalent interactions, the present invention uses modified sodium alginate and hydroxylated porcine small intestinal submucosal layer as raw materials to design a hemostatic material that can quickly achieve self-gelling. The hemostatic material has good hydrophilicity and liquid absorption capacity, can achieve powder-gel transformation in a short time, form a stable physical barrier, has platelet-responsive characteristics, can promote platelet adhesion and activation, accelerate the body's coagulation process, and improve the mechanical properties and tissue adhesion of the material, and has good application prospects.
Claims
1. A self-gelling hemostatic material, characterized in that: The invention is prepared from the following raw materials in parts by weight: 1 to 5 parts of oxidized alginate modified by grafting of borate bonds and 0.01 to 1 part of hydroxylated small intestinal submucosal layer.
2. The self-gelling hemostatic material according to claim 1, characterized in that: The invention is prepared from the following raw materials in parts by weight: 1 part of oxidized alginate modified by grafting of borate bonds and 0.3 part of hydroxylated small intestinal submucosal layer.
3. The self-gelling hemostatic material according to claim 1, characterized in that: The self-gelling hemostatic material is a self-gelling hemostatic hydrogel material or a self-gelling hemostatic powder material.
4. The self-gelling hemostatic material according to any one of claims 1 to 3, characterized in that: The borate bond grafted modified oxidized alginate is 3-aminophenylboronic acid grafted modified oxidized alginate, and the oxidized alginate is preferably oxidized sodium alginate; the hydroxylated small intestinal submucosa is small intestinal submucosa modified by 3-amino-1,2-propanediol, and the small intestinal submucosa is preferably porcine small intestinal submucosa.
5. The self-gelling hemostatic material according to claim 4, characterized in that: The synthesis method of the borate bond graft-modified oxidized alginate comprises the following steps: (1) dissolving alginate and an oxidant in a solvent, and obtaining oxidized alginate after reaction; (2) dissolving oxidized alginate and an activator in a solvent, adding 3-aminophenylboric acid solution, and obtaining oxidized alginate grafted with borate bonds after reaction.
6. The self-gelling hemostatic material according to claim 5, characterized in that: In step (1), the oxidant is sodium periodate; the mass ratio of the alginate to the oxidant is 1:0.1-0.5; the solvent of the reaction is an organic solvent; the reaction temperature is 10-40°C and the reaction time is 4-8 hours; In step (2), the activator is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; the solvent of the reaction is an inorganic solvent; the molar ratio of the oxidized alginate, the activator and the 3-aminophenylboronic acid is 1:1-5:1-3; the solvent in the 3-aminophenylboronic acid solution is an organic solvent; the reaction temperature is 10-40°C and the reaction time is 20-30 hours.
7. The self-gelling hemostatic material according to claim 4, characterized in that: The synthesis method of the hydroxylated small intestinal submucosa comprises the following steps: (i) reacting the small intestinal submucosa, acid and enzyme to obtain a small intestinal submucosa digestive fluid; (ii) The digestive juice of the small intestinal submucosa, 3-amino-1,2-propanediol and an activator are dissolved in a solvent, and after reaction, a hydroxylated small intestinal submucosa is obtained.
8. The self-gelling hemostatic material according to claim 7, characterized in that: In step (i), the acid is hydrochloric acid; the enzyme is pepsin; the mass ratio of the small intestinal submucosal layer to the enzyme is 1:0.05-0.3; the reaction temperature is 20-30°C and the reaction time is 20-100 hours; In step (ii), the activator is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride; the mass ratio of the small intestinal submucosal layer to 3-amino-1,2-propanediol is 1:0.5-6; the amount of 3-amino-1,2-propanediol to the activator is 1:0.5-5; the solvent is an inorganic solvent; the reaction temperature is 10-40°C and the reaction time is 20-30 hours.
9. A method for preparing the self-gelling hemostatic material according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: dissolving the oxidized alginate modified by grafting of borate bonds and the hydroxylated small intestinal submucosa in solvents respectively, then mixing the oxidized alginate solution modified by grafting of borate bonds and the hydroxylated small intestinal submucosa solution, and adjusting the pH to form a self-gelling hemostatic hydrogel material; or, the method further comprises the following steps: freeze-drying and grinding the hydrogel to obtain a self-gelling hemostatic powder material.
10. Use of the self-gelling hemostatic material according to any one of claims 1 to 8 in the preparation of a hemostatic material.
Citation Information
Patent Citations
Self-healing hydrogel wound dressing loaded with antibacterial peptide and preparation method of self-healing hydrogel wound dressing
CN114225097A
Porcine decellularized small intestinal submucosa extracellular matrix hydrogel combined with silk fibroin as well as preparation method and application of porcine decellularized small intestinal submucosa extracellular matrix hydrogel
CN114848893A
